BioNTech, Germany and Singapore
Digest more
The company said it would exit operations at some manufacturing plants in Germany and Singapore, and that as many as 1,860 ...
BioNTech, once celebrated for its COVID-19 vaccines, is grappling with falling demand, restructuring and the departure of its ...
BioNTech is planning site closures affecting up to 1,860 jobs and will buy back $1 billion in shares after announcing the ...
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that it has authorized a new share repurchase program (the “Program”), under which the Company may repurchase American ...
BioNTech shares sank yesterday as disappointing Q1 results prompted layoffs. But long-term investors still have ample reasons ...
The closed sites include some that came with its $1.25 billion takeover of CureVac last year, and BioNTech has said it hopes ...
Germany s BioNTech said Tuesday it will halt operations at several sites, in a move affecting up to 1,860 jobs, as sales of ...
Detailed price information for Praxis Precision Medicines Inc (PRAX-Q) from The Globe and Mail including charting and trades.
BioNTech (NasdaqGS:BNTX) has started five additional pivotal oncology trials in collaboration with Bristol Myers Squibb. The company has expanded its oncology pipeline with new candidates entering ...
The action affects BioNTech sites in Germany and Singapore, where the company expects to have excess capacity.
BERLIN, May 6 (Reuters) - A German government spokesperson said on Wednesday that the loss of BioNTech vaccine production in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results